目的 探討固本咳喘膠囊聯(lián)合硫酸特布他林霧化液治療兒童支氣管哮喘的臨床療效。方法 選取2019年7月—2020年7月在信陽市第一人民醫(yī)院治療的136例支氣管哮喘患兒，根據(jù)隨機數(shù)字表法分為對照組和治療組，每組各68例。對照組吸入硫酸特布他林霧化液，患兒體質(zhì)量≥20 kg用藥5 mg，3次/d；患兒體質(zhì)量≤20 kg用藥2.5 mg，4次/d。治療組在對照組的基礎(chǔ)上口服固本咳喘膠囊，3粒/次，3次/d。兩組患兒連續(xù)用藥7 d。觀察兩組患者臨床療效，比較治療前后兩組患兒臨床癥狀好轉(zhuǎn)時間，肺功能第1秒用力呼氣量（FEV1）、用力肺活量（FVC）、1秒率（FEV1/FVC）和最大呼氣峰流速（PEF）指標(biāo)，血清白細胞介素4（IL-4）、白細胞介素17（IL-17）、干擾素-γ（IFN-γ）和轉(zhuǎn)化生長因子β2（TGF-β2）水平及不良反應(yīng)情況。結(jié)果 治療組總有效率明顯高于對照組（P<0.05）。治療后，治療組癥狀好轉(zhuǎn)時間均明顯早于對照組（P<0.05）。治療后，兩組患兒肺功能FEV1、FVC、FEV1/FVC、PEF指標(biāo)均高于治療前（P<0.05），且治療組明顯高于對照組（P<0.05）。治療后，兩組患兒血清炎性因子IL-17、IL-4、IFN-γ、TGF-β2水平均低于治療前（P<0.05），且治療組明顯低于對照組（P<0.05）。治療期間，治療組不良反應(yīng)總發(fā)生率明顯低于對照組（P<0.05）。結(jié)論 固本咳喘膠囊聯(lián)合硫酸特布他林霧化液治療支氣管哮喘患兒，臨床效果明顯，能有效恢復(fù)肺功能，降低炎性反應(yīng)，用藥安全。

Objective To investigate the curative effect of Guben Kechuan Capsules combined with terbutaline in treatment of bronchial asthma in children. Methods Children (136 cases) with bronchial asthma in the First People's Hospital of Xinyang from July 2019 to July 2020 were randomly divided into control and treatment groups, and each group had 68 cases. Children in the control group were inhalation administered with Terbutaline Sulphate Solution for Nebulization, 5 mg for the weight more than 20 kg, three times daily, 2.5 mg for the weight less than 20 kg, four times daily. Children in the treatment group were po administered with Guben Kechuan Capsules on the basis of the control group, 3 grains/time, three times daily. Children in two groups were treated for 4 weeks. After treatment, the clinical efficacy was evaluated, and the improvement time of clinical symptoms, the lung function of FEV1, FVC, FEV1/FVC and PEF, the serum levels of IL-17, IL-4, IFN-γ and TGF-β2, and adverse reactions in two groups before and after treatment were compared. Results The total clinical effective rate in the treatment group was significantly higher than that in the control group (P < 0.05). After treatment, the time of symptom improvement in the treatment group was significantly earlier than that in the control group (P < 0.05). After treatment, the pulmonary function indexes of FEV1, FVC, FEV1/FVC, and PEF in two groups were significantly higher than those before treatment (P < 0.05), and which in the treatment group were significantly higher than those in the control group (P < 0.05). After treatment, the levels of serum inflammatory factors IL-17, IL-4, IFN-γ and TGF-β2 in two groups were significantly lower than those before treatment (P < 0.05), and which in the treatment group were significantly lower than those in the control group (P < 0.05). During the treatment, the total incidence of adverse reactions in the treatment group was significantly lower than that in the control group (P < 0.05). Conclusion Guben Kechuan Capsules combined with terbutaline in treatment of bronchial asthma in children has obvious clinical effect, which can effectively restore the pulmonary function, reduce the inflammatory reaction, and the medication is safe.

R974

國家自然科學(xué)基金資助項目（81574020）